{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T03:38:03Z","timestamp":1768793883115,"version":"3.49.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The efficacy of irinotecan plus continuous trastuzumab beyond progression in patients with gastric cancer previously treated with trastuzumab plus standard first-line chemotherapy has not been reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer who were previously treated with trastuzumab received trastuzumab every 3 weeks and irinotecan every 2 weeks. The primary endpoint was the overall response rate (ORR), and the secondary endpoints included progression-free survival (PFS), 6-month survival rates, safety, and subgroup analysis by HER2 status.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixteen patients were enrolled in a 3-year pre-planned registration period. This study was prematurely closed due to poor patient accrual. The ORR and disease control rate were 6.7% (95% CI, 0.2-32.0) and 53.3% (95% CI, 26.6-78.7). The median PFS and overall survival (OS) were 2.4 months (95% CI, 0.0-5.2) and 9.7 months (95% CI, 8.2-11.2), respectively. The most frequently reported grades 3-4 adverse events were neutropenia (40%), anemia (27%), anorexia (33%), and fatigue (33%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>With only 16 patients enrolled, the present study has very low power to detect any clinical benefit of trastuzumab plus irinotecan beyond disease progression in patients with HER2-positive advanced gastric cancer who previously received trastuzumab.<\/jats:p>\n                  <jats:p>Trial Identifier: UMIN000007636.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyab062","type":"journal-article","created":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T05:00:52Z","timestamp":1641013252000},"page":"340-e374","source":"Crossref","is-referenced-by-count":6,"title":["Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-0015","authenticated-orcid":false,"given":"Yasuyuki","family":"Kawamoto","sequence":"first","affiliation":[{"name":"Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Meguro","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hokkaido Gastroenterology Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuteru","family":"Hatanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Uebayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Kitami Hospital, Kitami, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Okuda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Iwanaga","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sapporo-Kosei General Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Iwamizawa Municipal General Hospital, Iwamizawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Oba","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuh","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Misawa City Hospital, Misawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"issue":"17","key":"2022050615373337000_CIT0001","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.19.03077","article-title":"Randomized, Phase II Study of Trastuzumab Beyond Progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study).","volume":"38","author":"Makiyama","year":"2020","journal-title":"J Clin Oncol."},{"issue":"25","key":"2022050615373337000_CIT0002","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer.","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med."},{"issue":"7","key":"2022050615373337000_CIT0003","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study.","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology."},{"issue":"4","key":"2022050615373337000_CIT0004","doi-asserted-by":"crossref","first-page":"499","DOI":"10.21037\/jgo.2016.06.16","article-title":"Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience.","volume":"7","author":"Al-Shamsi","year":"2016","journal-title":"J Gastrointest Oncol."},{"issue":"15","key":"2022050615373337000_CIT0005","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","article-title":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer\u2014a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).","volume":"47","author":"Thuss-Patience","year":"2011","journal-title":"Eur J Cancer."},{"issue":"7","key":"2022050615373337000_CIT0006","first-page":"1033","article-title":"[Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].","volume":"21","author":"Futatsuki","year":"1994","journal-title":"Gan To Kagaku Ryoho."},{"issue":"1","key":"2022050615373337000_CIT0007","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/jjco\/hyh006","article-title":"Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy.","volume":"34","author":"Chun","year":"2004","journal-title":"Jpn J Clin Oncol."},{"issue":"4","key":"2022050615373337000_CIT0008","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/030089160308900411","article-title":"Single-agent irinotecan as second-line treatment for advanced gastric cancer","volume":"89","author":"Kanat","year":"2003","journal-title":"Tumori"},{"key":"2022050615373337000_CIT0009"},{"issue":"4","key":"2022050615373337000_CIT0010","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","article-title":"Estimates of cancer incidence and mortality in Europe in 2008.","volume":"46","author":"Ferlay","year":"2010","journal-title":"Eur J Cancer."},{"issue":"9742","key":"2022050615373337000_CIT0011","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in \u00adcombination with chemotherapy versus chemotherapy alone\u00a0for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised\u00a0controlled trial.","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"2022050615373337000_CIT0012","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol."},{"issue":"10111","key":"2022050615373337000_CIT0013","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet."},{"issue":"11","key":"2022050615373337000_CIT0014","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol."},{"issue":"35","key":"2022050615373337000_CIT0015","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.","volume":"31","author":"Hironaka","year":"2013","journal-title":"J Clin Oncol."},{"issue":"10","key":"2022050615373337000_CIT0016","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jnci\/djh131","article-title":"Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.","volume":"96","author":"Pegram","year":"2004","journal-title":"J Natl Cancer Inst."},{"issue":"17","key":"2022050615373337000_CIT0017","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/sj.onc.1202132","article-title":"Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.","volume":"17","author":"Pietras","year":"1998","journal-title":"Oncogene."},{"issue":"5","key":"2022050615373337000_CIT0018","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1634\/theoncologist.2007-0204","article-title":"Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.","volume":"13","author":"Bullock","year":"2008","journal-title":"Oncologist."},{"issue":"25","key":"2022050615373337000_CIT0019","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.2007.11.9776","article-title":"Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.","volume":"25","author":"Bartsch","year":"2007","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022050615373337000_CIT0020","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/JCO.2004.06.557","article-title":"Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.","volume":"22","author":"Tripathy","year":"2004","journal-title":"J Clin Oncol."},{"issue":"12","key":"2022050615373337000_CIT0021","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2008.19.6618","article-title":"Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26\/breast international group 03-05 study.","volume":"27","author":"von Minckwitz","year":"2009","journal-title":"J Clin Oncol."},{"issue":"19","key":"2022050615373337000_CIT0022","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","article-title":"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN\u2014a randomized, phase III study.","volume":"32","author":"Satoh","year":"2014","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022050615373337000_CIT0023","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","article-title":"Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study.","volume":"18","author":"Thuss-Patience","year":"2017","journal-title":"Lancet Oncol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/5\/340\/43590624\/oyab062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/5\/340\/43590624\/oyab062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T15:38:32Z","timestamp":1651851512000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/5\/340\/6550607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3,18]]},"published-print":{"date-parts":[[2022,5,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyab062","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,3,18]]}}}